Cipher PharmaceuticalsCPHRF 96 Interest Coverage is 109.71 as of Mar. 2026, which is 820% above its 10-year median of 11.92. GuruFocus rates CPHRF with a GF Score™ of 96/100 and a GF Value™ of $12.20 (Fairly Valued). The stock has 5 warning signs investors should review. Among 685 Drug Manufacturers companies, Cipher Pharmaceuticals ranks better than 63.5% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Cipher Pharmaceuticals's
Operating Income
for the
three
months ended in Mar. 2026 was $5.60 Mil. Cipher Pharmaceuticals's Interest Expense for the
three
months ended in Mar. 2026 was $-0.05 Mil.
Cipher Pharmaceuticals's interest coverage for the quarter that ended in Mar. 2026 was 109.71.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Cipher Pharmaceuticals's Interest Coverage or its related term are showing as below:
CPHRF'
s Interest Coverage Range Over the Past 10 Years
Min: 1.48 Med: 11.92 Max: 141.66
Current: 26.81
CPHRF's Interest Coverage is ranked better than 63.5% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs CPHRF: 26.81
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Cipher Pharmaceuticals Interest Coverage Related Terms
Cipher Pharmaceuticals Interest Coverage Historical Data
* Premium members only.
The historical data trend for Cipher Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipher Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Cipher Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipher Pharmaceuticals (CPHRF) has a Interest Coverage of 109.71 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Cipher Pharmaceuticals and its competitors. This is 820% above median its historical median of 11.92. Over the past decade, Cipher Pharmaceuticals' Interest Coverage has ranged from 1.48 to 141.66. According to the industry distribution chart, Cipher Pharmaceuticals ranks #250 out of 685 companies in the Drug Manufacturers industry, placing it in the top 36.5%.
Is Cipher Pharmaceuticals' Interest Coverage too high?
Cipher Pharmaceuticals' current Interest Coverage of 109.71 is 820% above median its 10-year median of 11.92. Over the past 10 years, this metric has ranged from a low of 1.48 to a high of 141.66. The Drug Manufacturers industry median Interest Coverage is 12.78. Cipher Pharmaceuticals' value of 109.71 is 758.5% above this industry median. Based on the distribution chart, Cipher Pharmaceuticals ranks #250 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cipher Pharmaceuticals has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipher Pharmaceuticals ranks #250 out of 685 companies for Interest Coverage. This puts Cipher Pharmaceuticals in the upper half of its industry. The industry median Interest Coverage is 12.78. Cipher Pharmaceuticals' value of 109.71 is 758.5% above this benchmark. Historically, Cipher Pharmaceuticals' own Interest Coverage has ranged from 1.48 to 141.66 over the past decade. While the company's 10-year median is 11.92 vs. the industry median of 12.78, Cipher Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipher Pharmaceuticals's current Interest Coverage of 109.71 is 758.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Cipher Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipher Pharmaceuticals's current Interest Coverage is 109.71, which is 820% above median its own 10-year median of 11.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (CPHRF) is currently considered Fairly Valued. The stock's GF Value™ is $12.20, compared to a current price of $11.77 — trading 3.5% below its estimated fair value. The current Interest Coverage is 109.71, which is 820% above median its 10-year median of 11.92 and 758.5% above the Drug Manufacturers industry median of 12.78. Cipher Pharmaceuticals' overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Cipher Pharmaceuticals (CPHRF), the current Interest Coverage is 109.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipher Pharmaceuticals (CPHRF) Overvalued in 2026?
Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued.
The current stock price of $11.77 is trading 3.5% below its estimated GF Value™ of $12.20.
GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.
Key valuation signals for CPHRF:
Interest Coverage: 109.71 (820% above median its 10-year median of 11.92)
GF Value™: $12.20 vs. price of $11.77 (3.5% below fair value)
Industry Position: 758.5% above the Drug Manufacturers median (#250 of 685)
No single metric tells the full story. See the CPHRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
96GF Score
Get the complete analysis for CPHRF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHRF has been successfully added to your 
